Evidence map›Paper›PMID 39891783›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Red light therapy for patients with chemotherapy-induced alopecia.

Lucy Rose, Layna Mager, Maria Hordinsky, Brittany Dulmage

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lucy RoseThe Ohio State University College of Medicine, Columbus, OH, USA. Lucy.rose@osumc.edu.
Layna MagerThe Ohio State University College of Medicine, Columbus, OH, USA.
Maria HordinskyThe Ohio State University College of Medicine, Columbus, OH, USA.
Brittany DulmageThe Ohio State University College of Medicine, Columbus, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have taken great interest in the topic of red light therapy (RLT) for the treatment of hair loss secondary to cancer therapies. On April 7, 2024, we searched through two private Facebook groups (Fig. 1) intended for patients who used scalp cooling for prevention of chemotherapy-induced hair loss. In these groups, we found several posts inquiring about the use of RLT (Fig. 2). Posts ranged from patients asking if others in the group have used RLT, if RLT is safe to use while scalp cooling, and recommendations for how long to wait to initiate RLT after chemotherapy infusions are completed. Despite the rise in popularity of RLT for the management of hair loss, to date, only two clinical trials have included patients with cancer treatment-induced hair loss, which showed higher hair counts and increased quality of life in those who used RLT [1, 2]. Furthermore, no formal recommendations from oncologists or scalp cooling companies have been made to help guide patients when considering using RLT.

Indexed as

AlopeciaAntineoplastic AgentsPhototherapyHumansNeoplasmsQuality of LifeScalpSocial MediaAntineoplastic Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.